Quantitative modeling of the high-throughput production and in vivo kinetics of (drug-encapsulating) liposomes.
In developing liposomes for in vivo use, it is important to design the liposomes to have optimal in vivo kinetics, and it is also necessary to identify optimal high-throughput production conditions for these liposomes. Previous work has not definitively established the general relationship between l...
Main Author: | Albert Wong |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2859061?pdf=render |
Similar Items
-
Drug-encapsulating EGF-sensitive liposomes for EGF-overexpressing cancer therapies
by: Wong, Albert, S.M. Massachusetts Institute of Technology
Published: (2010) -
In vivo and in vitro toxicity evaluation of liposome-encapsulated sirolimus
by: Murilo Batista Abud, et al.
Published: (2019-09-01) -
In vivo monitoring of liposomal encapsulated siRNA delivery
by: Kenny, Gavin David
Published: (2010) -
Liposomal Drug Encapsulation in the Treatment of Rheumatoid Arthritis
by: Shaw, I. H.
Published: (1977) -
Qualitative and quantitative analysis of hematoporphyrin and doxorubicin co-encapsulated in the liposomes
by: Ying-Jun Zhou, et al.
Published: (2007)